ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
äŒæ¥ã³ãŒãICCC
äŒç€ŸåImmuCell Corp
äžå Žæ¥May 01, 1987
æé«çµå¶è²¬ä»»è
ãCEOãte Boekhorst (Olivier)
åŸæ¥å¡æ°69
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 01
æ¬ç€Ÿæåšå°56 Evergreen Drive
éœåžPORTLAND
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·04103
é»è©±çªå·12078782770
ãŠã§ããµã€ãhttps://immucell.com/
äŒæ¥ã³ãŒãICCC
äžå Žæ¥May 01, 1987
æé«çµå¶è²¬ä»»è
ãCEOãte Boekhorst (Olivier)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã